AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 21 min read$OPK

OPKO shares convertible after stock climbs above trigger; $121M notes convertible into equity

OPKO Health's stock (OPK) surpassed $1.495, triggering convertibility of $121M in 3.75% Convertible Senior Notes due 2029. Holders can convert notes into 869.5652 shares per $1,000 principal until Dec 31, 2026. The company will satisfy conversions with common stock, per its SEC filing.

Original reporting
tradingview.com
Published Oct 2, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OPKO shares convertible after stock climbs above trigger; $121M notes convertible into equity — source image
Source · tradingview.com
Decision brief

The 30-second read

$OPKBearishMed
01

Why it matters

The conversion will increase outstanding shares, likely pressuring the stock price due to dilution.

02

Market read

Primary corporate action for OPKO; relevant for shareholders and potential note holders.

03

What to watch

Potential for early conversion incentives or strategic investors stepping in could mitigate dilution impact.

Relevance 7/10Novelty 8/10Timing: immediate today

Background

OPKO Health filed an 8‑K reporting that its 3.75% convertible senior notes due 2029 have met the conversion trigger.

Company-level read

Ticker impact

$OPKBearishHigh confidence
Context

Conversion trigger disclosed in 8‑K as stock closed above $1.495 for 20 days, making $121M of 3.75% notes convertible.

Expected impact

likely pressure as market prices in dilution from note conversion

Evidence & confidence

The conversion terms are now active; holders will receive 869.5652 shares per $1,000, expanding float.

Market effects

Sector

May affect other biotech and specialty pharma firms with similar convertible financing structures.

Regional

Limited to US markets; no broader regional effect.

Global

Low global relevance beyond investors tracking OPKO.

Counterpoint

What could challenge this read

If conversion proceeds smoothly, the cash infusion could improve balance sheet and support future growth.

Key entities

  • company
    OPKO Health, Inc.

    Issuer of the convertible notes now triggering conversion.

Read at source← All news

Related articles

OCT 15
$LHHighAI 9/10

Labcorp to Acquire BioReference Assets From OPKO for $872M

Labcorp agreed to acquire OPKO Health's remaining BioReference Health assets for up to $872M, including clinical diagnostics and the 4Kscore prostate cancer test. OPKO shares rose 20% premarket. The deal follows prior acquisitions of BioReference units, allowing OPKO to focus on biopharmaceuticals. Labcorp expects the acquired businesses to generate $250M in annual revenue.

hoodline.com3 min
OCT 15
$LHHighAI 9/10

Labcorp outlays up to $872m to acquire BioReference’s laboratory assets

Labcorp is acquiring laboratory assets from BioReference Health, an OPKO Health subsidiary, for up to $872m. The deal includes BioReference's clinical and women's health testing services, urology, corrections, and the 4Kscore prostate cancer test. Labcorp will pay $722m upfront, with up to $150m in potential earnouts. The transaction aims to expand Labcorp's diagnostic services and streamline OPKO's operations.

finance.yahoo.com2 min
OCT 15
$OPKHighAI 9/10

OPKO Health Stock Jumps 16% On BioReference Asset Sale To Labcorp

OPKO Health (OPK) rose 16.13% to $1.5910 after agreeing to sell BioReference Health assets to Labcorp for $722M, with up to $150M in earnouts. The deal includes clinical testing businesses and the 4Kscore Test. Trading volume surged to 30.99M shares. OPK shares have ranged from $0.98 to $1.75 over the past year.

rttnews.com3 min
OCT 15
$OPKHighAI 9/10

Why is Opko Health stock surging today?

Opko Health (OPK) shares rose 11.7% after Labcorp agreed to buy BioReference Health, its lab services unit, for $722M cash, with up to $150M more tied to 4Kscore Test revenue. The deal includes 80+ patient service centers and the FDA-approved 4Kscore blood test. OPK's market cap is below $722M, and the stock had been declining before the news. The broader market was mixed, with the Nasdaq down 1.0%.

investing.com6 min